Biotech

LifeSpan Vision Ventures Invests in SENISCA

2024-03-19 17:00 420

NORWALK, Conn., March 19, 2024 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm specializing in longevity biotech investments, today announced an investment in SENISCA, an RNA therapeutics spinout from the University of Exeter. The company has developed proprietary technology that har...

Cognizant to apply generative AI to enhance drug discovery for pharmaceutical clients with NVIDIA BioNeMo

2024-03-19 12:01 743

Cognizant's AI and industry expertise, combined with the NVIDIA BioNeMo generative AI platform, create a strong foundation to improve outcomes in the healthcare and life sciences sectors TEANECK, N.J., March 19, 2024 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) is advancing the application of genera...

Sanyou Bio and BioGeometry join forces to create a next-generation Antibody Drug Discovery Platform driven by AIGC

2024-03-19 08:00 668

SHANGHAI, March 18, 2024 /PRNewswire/ -- Recently, BioGeometry and Sanyou Bio jointly announced the signing of a strategic partnership agreement. BioGeometry is a digital biology pioneer company that specializes in AI-driven protein design and R&D platform. Sanyou Bio is a world-leading high-tec...

KeChow Pharma Announces NMPA Approval of Tunlametinib (HL-085) as the First Targeted Therapy for Patients with NRAS Mutated Advanced Melanoma and Previously Treated with PD-1/PD-L1

2024-03-18 18:02 917

-- Tunlametinib is poised to be a potential best-in-class MEK inhibitor based on positive data from the pivotal Phase 2 study SHANGHAI, March 18, 2024 /PRNewswire/ -- KeChow Pharma, a commercial-stage pharmaceutical company focused on developing and commercializing differentiated small molecule ...

ImmVira's oncolytic product MVR-T3011 IT Intratumoral Injection Receives FDA Fast Track Designation for HNSCC Treatment

2024-03-15 13:56 1235

SHENZHEN, China, March 15, 2024 /PRNewswire/ -- ImmVira has recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for oncolytic virus product MVR-T3011 IT (intratumoral injection) for the treatment of recurrent or metastatic head and neck squamous ...

Biotheus Expanded Their Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific Antibody-Drug Conjugates

2024-03-15 12:34 1178

ZHUHAI, China, March 15, 2024 /PRNewswire/ -- On March 14, 2024, Biotheus Inc. (Biotheus), a clinical-stage biotech company focusing on the discovery and development of biologics for oncology and inflammatory diseases, and Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma,03692.HK), China's le...

Advancing Healthcare in Uzbekistan: BGI Genomics CEO's Vision Shared on Uzbekistan's National Television

2024-03-15 07:55 1968

HONG KONG, March 15, 2024 /PRNewswire/ -- Zhao Lijian, CEO of BGI Genomics, provided fresh insights on the company's vision during an exclusive interview withUzbekistan's National Television on Channel O'zbekiston24. This discussion was part of the "Focusing on the History of Uzbekistan-China Rel...

I-Mab Reports Full Year 2023 Financial Results and Business Update

2024-03-15 05:00 2729

* Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end ofMarch 2024 * Uliledlimab (CD73 antibody) on track to file an IND in combination with chemotherapy and checkpoint inh...

D3 Bio Appoints Dr. Antoine Yver as Independent Board Member

2024-03-14 22:30 1480

SHANGHAI, March 14, 2024 /PRNewswire/ -- D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs, welcomesAntoine Yver, MD. ,MSc. as the new independent board member, effectiveMarch 4, 2024. Dr. Yver has 34 years of e...

European Wellness and Sabah Government to Propel State into World-Class Medical Wellness Tourism Biotech Hub

2024-03-14 18:46 2614

KOTA KINABALU, Malaysia, March 14, 2024 /PRNewswire/ -- European Wellness, a leading name in health and wellness, announces a groundbreaking collaboration with theSabah state government, aimed at positioning Sabah as a premier destination for medical wellness tourism on the global stage. Chief...

Study of Kintor's c-Myc Degrader Published in Subsidiary Journal of Nature

2024-03-14 12:22 1111

SUZHOU, China, March 14, 2024 /PRNewswire/ -- Kintor Pharmaceutical Limited (" Kintor Pharma", HKEX: 9939.HK), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announces that Kintor and its cooperative partner had published an article namedMY...

Fapon Empowers Indian IVD Manufacturers at Medical Fair India 2024

2024-03-14 11:35 1664

DONGGUAN, China, March 14, 2024 /PRNewswire/ -- Fapon, a global leading life sciences company, continues its commitment in empowering the Indian IVD industry at Medical Fair India 2024, which is held fromMarch 13 to 15 at Mumbai, India. As one of the most significant medical trade fairs in India,...

YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024

2024-03-13 20:00 1079

SHANGHAI, March 13, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company pioneering inin vivo gene editing therapies, today announced participation in TIDES Asia 2024, March 19th to 21st, 2024, at the Westin Miyako Kyoto inKyoto, Japan. TIDES Asia

Novel Molecules From Generative AI to Phase II: First Novel TNIK Inhibitors for Fibrotic Diseases Discovered and Designed Using Generative AI

2024-03-13 08:00 2069

* A study published in Nature Biotechnology presents the entire journey of INS018_055, from AI algorithms to Phase II clinical trials for the first time. * Raw data from 13 preclinical experiments and 3 clinical trials referenced in this study can be accessed by visiting Insilico'sdata room <...

Aegros Limited proposes to issue debentures in a series of tranches up to an aggregate face value of AUD25 million for subscription by investors

2024-03-13 06:22 2006

SYDNEY, March 13, 2024 /PRNewswire/ -- Aegros Limited ACN 618 589 101 (the Issuer) proposes to issue debentures (in the form of loan notes) in a series of tranches up to an aggregate face value of AUD25 million of (Debentures) for subscription by investors (Investors). The Issuer will invest the ...

GenScript Biotech Announces 2023 Annual Results with a Five-Year CAGR stands at 30%

2024-03-12 20:15 2186

R&D Innovation to Lead the Future, Deepening Customer Value Creation * Sustained High Revenue Growth: GenScript Group's five-year CAGR stands at an impressive 30%, with a strong global operation and stable cash flow. In 2023, the group's best-in-class cell therapy product CARVYKTI®, achieved sa...

Longbio Pharma Presented Positive Phase 1 Results for LP-003 at 2024AAD

2024-03-12 20:00 1153

SAN DIEGO, March 12, 2024 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio Pharma"), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, hematology, ophthalmology, and other autoimmune and rare diseases, ...

TFS HealthScience Unveils Asia Pacific Expansion, Elevating Patient Access and Innovation

2024-03-12 10:52 1601

LUND, Sweden, March 12, 2024 /PRNewswire/ -- TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), announces its expansion into the Asia Pacific (APAC) region, with the establishment of an operational base in Melbourne, Australia. This strategic move marks a significant m...

SK Biopharmaceuticals Announces 100,000 Patients Globally Have Been Treated with Cenobamate Through Sales of XCOPRI® and ONTOZRY® in the U.S., Europe, Israel, and Canada

2024-03-12 08:00 1372

Milestone Coincides with SK Biopharmaceuticals' Global Plan Expanding Cenobamate Access to More Than 100 Markets Worldwide SEOUL, South Korea and ROME, March 12, 2024 /PRNewswire/ -- SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous system (CN...

ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive Topline Results

2024-03-11 17:00 1784

SEOUL, South Korea, March 11, 2024 /PRNewswire/ -- ImmunAbs, a leading clinical-stage biotechnology company focused on developing novel antibody therapeutics, today announced the successful completion of the Phase 1 clinical trial for IM-101. IM-101 is a humanized monoclonal antibody targeting...

12345 ... 143